Back

Anders Martin-Löf has been appointed as the new CFO of Oncopeptides

Stockholm – August 9, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Anders Martin-Löf, has been appointed as the new CFO of Oncopeptides and will join the company in November.

CFO Birgitta Ståhl has decided to step down as the CFO as the Company expands the organization in Europe and the US, following a successful preparation and execution of Oncopeptides’ IPO. She will continue to work in the Company.

Anders has extensive life science experience in financial, strategic and commercial positions in both public and private entities. The last decade he has been the CFO of Raysearch and Wilson Therapeutics. During this period Raysearch developed a global commercial footprint and Wilson Therapeutics went public on Nasdaq OMX and later acquired by Alexion. Anders brings broad knowledge from companies with international presence and his experience will be important to further develop the Oncopeptides organization.

CEO comments
“We are looking forward to Anders joining Oncopeptides and its management team. He will have an important operational and strategic role in the company given our agenda as a company” said Jakob Lindberg, CEO of Oncopeptides.

For further information, please contact:
Jakob Lindberg, CEO of Oncopeptides
E-mail: es.se1534781379ditpe1534781379pocno1534781379@greb1534781379dnil.1534781379bokaj1534781379
Telephone: +46 (0)8 615 20 40

Rein Piir, Head of Investor Relations at Oncopeptides
E-mail: es.se1534781379ditpe1534781379pocno1534781379@riip1534781379.nier1534781379
Cell phone: +46 (0)70 853 72 92

The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person above, on August 9, 2018 at 08.30 (CET).

About Oncopeptides
Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. The company focus on the development of the lead product candidate Ygalo®, an innovative, Peptidase Enhanced Cytotoxic (PEnCs). Ygalo® is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The current clinical study program is intended to demonstrate better results from ­treatment with Ygalo® compared with established alternative drugs for patients with late-stage multiple myeloma. Ygalo® will potentially provide physicians with a new treatment option for patients suffering from this serious disease.

Visit www.oncopeptides.se for more information.


Source: Oncopeptides